IPO Adamas Pharmaceuticals (ADMS) is a specialty pharmaceutical company that focuses on chronic disorders of the central nervous system, or CNS. Adamas is developing ADS-5102 for levodopa induced dyskinesia, and chronic behavioral symptoms associated with traumatic brain injury. Adamas plans to commercialize their wholly owned product candidates, if approved, by developing a specialty CNS sales force to reach high volume prescribing neurologists and psychiatrists in the United States.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
No comments:
Post a Comment